Biotech

Obesity and metabolic disease are now understood to be the upstream driver of most expensive chronic conditions: type 2 diabetes, cardiovascular disease, NASH, sleep apnoea, and increasingly addiction and neurodegenerative outcomes. GLP-1 receptor agonists have crossed the threshold from a diabetes class to a multi-decade re-platforming of healthcare economics, with Eli Lilly and Novo Nordisk holding a structural duopoly on the injectable franchises. The next leg is oral GLP-1 (Lilly orforglipron, Novo amycretin), amylin co-agonists, and triple-agonists; each opens a new addressable cohort and resets payer-coverage debates.

Gene editing has crossed its own threshold. The Vertex / CRISPR Casgevy launch in sickle cell disease and beta-thalassemia is the first commercial proof that ex-vivo editing scales as a paid therapy. The question is now manufacturing economics and reimbursement design, not whether the science works. In-vivo editing (Intellia, Beam) is the next platform shift, with cardiovascular and liver-targeted indications first. AI-bio (Recursion, Schrödinger, AlphaFold-derived platforms) is no longer a thought experiment; the data flywheels are accumulating and the first AI-discovered candidates are reading out in clinic.

Edge sources we lean on: (1) GLP-1 prescription volume by payer cohort, with attention to commercial-plan coverage gates; (2) clinical readout calendars (especially for oral GLP-1 and in-vivo editors); (3) FDA approval pace by modality (cell, gene, mRNA, antibody) as a leading indicator of platform durability; (4) M&A premiums in mid-cap biotech as a check on whether large-cap pharma is paying for the pipeline gap; (5) manufacturing capacity announcements (CDMO, viral vector, fill-finish) where supply has been the bottleneck.